Gender Differences in Prevalence and Associated Factors of Dyslipidemia in Initial-Treatment and Drug-Naïve Schizophrenia Patients
DOI: https://doi.org/10.2147/ndt.s457631
IF: 2.989
2024-05-08
Neuropsychiatric Disease and Treatment
Abstract:Fang Deng, 1, 2, &ast Jun Ma 3, &ast 1 Department of Psychiatry, Wuhan Mental Health Center, Wuhan, Hubei, People's Republic of China; 2 Wuhan Hospital for Psychotherapy, Wuhan, Hubei, People's Republic of China; 3 Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun Ma, Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Zhangzhidong Road, Wuhan, Hubei, People's Republic of China, Email Background: Dyslipidemia is frequently comorbid with schizophrenia (SCZ), and both conditions often demonstrate significant gender differences in their clinical features. This study specifically focuses on investigating the prevalence of dyslipidemia and the factors that contribute to it in initial-treatment and drug-naïve (ITDN) SCZ patients, specifically focusing on gender differences. Methods: A total of 224 male ITDN SCZ patients and 424 female ITDN SCZ patients were included in this study. Socio-demographic and general clinical data of the patients were collected, and routine biochemical parameters, such as lipid levels, fasting blood glucose, thyroid function, renal function, and blood cell counts, were measured. Patients were also assessed for psychopathology and disease severity using the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Scale - Severity of Illness (CGI-SI), respectively. In addition, a lipids score was calculated for assessing the severity of dyslipidemia. Results: The study revealed that the prevalence of dyslipidemia in male patients was 34.02% (83/224), whereas 33.25% (141/424) in females, indicating no statistically significant difference (χ 2 = 0.04, p = 0.841). For males, the risk factors for dyslipidemia were high education levels and diastolic blood pressure (DBP), while red blood cell count (RBC) as a protective factor. Additionally, DBP was identified as a risk factor for dyslipidemia score. In females, systolic blood pressure (SBP) was identified as a risk factor for dyslipidemia, while being married and creatinine (CRE) levels were found to be protective factors. Moreover, SBP was revealed as a risk factor for dyslipidemia score. Conclusion: No significant gender differences were observed in the prevalence of dyslipidemia among the ITDN SCZ patients. However, notable gender differences were identified in the factors influencing dyslipidemia and its severity within this group. These findings suggest the necessity of implementing gender-specific interventions to address the potential risk factors associated with dyslipidemia. Keywords: gender difference, dyslipidemia, lipid levels, schizophrenia, drug-naïve Schizophrenia (SCZ) is a prevalent and chronic mental illness with a multifaceted etiology. 1 Recent research has highlighted a higher susceptibility to secondary endocrine and metabolic disorders among individuals with SCZ. 2 Notably, dyslipidemia, a widely prevalent metabolic disorder, frequently occurs in SCZ patients. 3,4 The presence of dyslipidemia in SCZ patients is significantly associated with elevated morbidity and mortality rates from cardiovascular diseases, as well as reduced life expectancy. 5 Additionally, dyslipidemia has been identified as a significant biological factor associated with cognitive impairment, suicide attempts, and aggressive behavior. 6–8 Hence, comprehensively understanding dyslipidemia in SCZ patients and delineating its clinical characteristics are essential for effective clinical management. There is increasing evidence suggesting that dyslipidemia may be present even before the onset of psychiatric disorders and during the first psychotic episode. 9,10 In individuals at risk for mental illness, including those with subthreshold symptoms, reductions in high-density lipoprotein (HDL) levels have been observed. 11 Moreover, genome-wide association analyses have shown shared genetic loci between SCZ and cardiovascular disease risk factors, such as high-density lipoprotein (HDL) and low-density lipoprotein (LDL). 12,13 These findings indicate that dyslipidemia is inherent in SCZ. Dyslipidemia generally exhibits significant gender differences in both diagnosis and treatment. 14–16 As observed in the general population, men tend to have a higher prevalence of cardiovascular disease compared to premenopausal women. However, after menopause, the prevalence of cardiovascular disease in women gradually increases to match that of men. 17,18 These disparities can be attributed, in large part, -Abstract Truncated-
psychiatry,clinical neurology